Exit Strategy Archives - covid19.ecambiomed.com

Summary:
COVID-19 Adaptive Exit Strategies are rapidly evolving with ongoing public and private learning, discussion and planning. Experience and outcomes are expected to continue to vary, from country to country, with global cooperation required to end the COVID-19 Pandemic.
Published for educational purposes and social benefit, not for profit. Not a recommendation or endorsement. Always consult your doctor for medical advice.

July 2021

FP | The Science Says Everyone Needs a COVID-19 Booster Shot—and Soon

sibiu1182021-07-31T10:59:50+00:00July 31st, 2021|

The biology of the delta variant has made mass revaccination an urgent necessity. The world has fought many battles against the novel coronavirus since January 2020, losing more than 4.2 [...]

GOV UK | News story COVID-19 vaccine surveillance report published | Infections prevented by COVID-19 vaccines doubles to 22 million and deaths prevented rises to 60,000

sibiu1182021-07-29T14:58:26+00:00July 29th, 2021|

Infections prevented by COVID-19 vaccines doubles to 22 million and deaths prevented rises to 60,000 Public Health England (PHE) has published its latest weekly COVID-19 vaccine surveillance report. Latest PHE estimates that [...]

VACCINES | Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand

sibiu1182021-07-21T09:20:29+00:00July 21st, 2021|

Abstract To overcome pandemics, such as COVID-19, vaccines are urgently needed at very high volumes. Here we assess the techno-economic feasibility of producing RNA vaccines for the demand associated with [...]

Public Citizen | How to Make Enough Vaccines for The World in One Year

sibiu1182021-07-21T08:24:56+00:00July 21st, 2021|

How to Make Enough Vaccine for the World in One Year - Public Citizen What would it take to produce enough coronavirus vaccine for the world in one year? In [...]

May 2021

THE NEW YORK TIMES | Reaching ‘Herd Immunity’ Is Unlikely in the U.S., Experts Now Believe

sibiu1182021-05-04T03:54:11+00:00May 3rd, 2021|

Experts Now Believe Widely circulating coronavirus variants and persistent hesitancy about vaccines will keep the goal out of reach. The virus is here to stay, but vaccinating the most vulnerable [...]

February 2021

THE LANCET | Covid-19: How the UK vaccine rollout delivered success, so far

sibiu1182021-03-28T13:51:51+00:00February 18th, 2021|

Chris Baraniuk, freelance journalist BMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n421 (Published 18 February 2021)Cite this as: BMJ 2021;372:n421 Reprinted for educational purposes and social benefit, not for profit. Chris Baraniuk explains the elements that have made the UK’s vaccination [...]

BLOOMBERG | Covid-19 Deals Tracker: 9.04 Billion Doses Under Contract

sibiu1182021-02-13T13:46:33+00:00February 13th, 2021|

Covid-19 Deals Tracker: 9.04 Billion Doses Under Contract We’re tracking 128 agreements between countries and drugmakers. The U.S. has secured 1.2 billion doses Linked for educational purposes and social benefit, [...]

CNN | Opinion: Dr Nicholas Christakis. Why the pandemic won’t be over until 2024

sibiu1182021-02-06T02:48:11+00:00February 6th, 2021|

Opinion: Why the pandemic won't be over until 2024 (video) Dr Nicholas Christakis, physician and social scientist at Yale University, explains the legacy Covid-19 will leave behind and his prediction [...]

January 2021

BBC NEWS | Covid: England and Scotland begin new lockdowns as cases rise

sibiu1182021-01-05T05:36:04+00:00January 5th, 2021|

People in all of England and most of Scotland must now stay at home except for a handful of permitted reasons, as new lockdowns begin in both nations. Schools have [...]

THE NEW YORK TIMES | Britain Opts for Mix-and-Match Vaccinations, Confounding Experts | If a second dose of one vaccine isn’t available, another may be substituted, according to new U.K. guidelines.

sibiu1182021-01-03T15:18:09+00:00January 2nd, 2021|

COVID-19 Greenbook chapter 14a "For individuals who started the schedule and who attend for vaccination at a site where the same vaccine is not available, or if the first product [...]